Kolon Life Science

Kolon Life Science FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Kolon Life Science (102940.KQ) as of Nov 3, 2026 is -112.89 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 24.51 % — a change of -560.68% (lower).

FCF Conversion

-112.89 %

YoY

-560.68%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Kolon Life Science is 2025 -112.89 % . FCF Conversion Rate (FCF/EBITDA) of Kolon Life Science was 2024 24.51 % . It decreases by -560.68% lower compared to the previous year.

The Kolon Life Science FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
110.55 KRW
Jan 1, 2019
55.20 KRW
Jan 1, 2020
23.27 KRW
Jan 1, 2021
1,498.29 KRW
Jan 1, 2022
-1,273.19 KRW
Jan 1, 2023
114.24 KRW
Jan 1, 2024
24.51 KRW
Jan 1, 2025
-112.89 KRW
The Kolon Life Science FCF Conversion history
YEARFCF ConversionYoY
-112.89 %-560.68%
24.51 %-78.55%
114.24 %-108.97%
-1,273.19 %-184.98%
1,498.29 %+6,339.41%
23.27 %-57.85%
55.20 %-50.07%
110.55 %-95.95%
2,726.24 %+2,784.10%
94.53 %-86.47%
698.71 %-1,504.75%
-49.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kolon Life Science Stock analysis

What does Kolon Life Science do? KOLON Life Science, Inc. generates revenue through its Chemical Business segment, which produces and sells raw drug products, antibacterial agents, water treatment agents, and functional material products for cosmetics. The Bio Business segment focuses on manufacturing and selling bio new medicines based on cell gene therapy products. The company's products target pharmaceutical and environmental markets, with raw drug products serving as essential components for new and generic drugs, while antibacterial agents and water treatment agents address healthcare and environmental purification needs. Functional materials for cosmetics represent a key product line within the Chemical Business segment. The company's revenue streams are derived from the sale of pharmaceutical raw materials, antibacterial agents, water treatment solutions, and cosmetic functional materials under the Chemical Business segment. The Bio Business segment contributes through the commercialization of advanced cell gene therapy-based medicines. Both segments operate within the pharmaceutical and environmental sectors, with the Chemical Business serving as the primary revenue driver for raw materials and environmental products, while the Bio Business targets innovative therapeutic solutions in the biopharmaceutical space. KOLON Life Science, Inc. sells its products to the pharmaceutical industry for drug development and manufacturing, as well as to environmental and cosmetic companies requiring specialized materials. The Chemical Business segment's raw drug products are used by pharmaceutical firms to produce new and generic drugs, while antibacterial agents and water treatment agents are supplied to healthcare and environmental purification sectors. Cosmetic functional materials are sold to the cosmetics industry for product development. The Bio Business segment's cell gene therapy products are targeted at biopharmaceutical companies seeking advanced treatment options. Kolon Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kolon Life Science stock

FCF Conversion Rate (FCF/EBITDA) of Kolon Life Science is -112.89 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Kolon Life Science changed from 24.51 % to -112.89 %, representing a -560.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Kolon Life Science since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Kolon Life Science with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Kolon Life Science

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Kolon Life Science